HOXC10 promotes nasopharyngeal carcinoma cell proliferation and migration by regulating PI3K/AKT pathway

Liping Wu¹, Guohong Qian²*, Yuqing Zheng³, Huizhen Zheng⁴
¹Department of Otolaryngology, Huzhou Central Hospital, Huzhou University, ²Department of Otolaryngology, Huzhou Central Hospital, ³School of Engineering, Huzhou University, Huzhou, Zhejiang Province 313000, ⁴Department of Otolaryngology, The Third Affiliated Hospital of Shanghai University (Wenzhou People’s Hospital), Wenzhou, Zhejiang Province 325000, China

*For correspondence: Email: Qianguohong_666@163.com; Tel: +86-0572-2555591

Sent for review: 7 May 2022 Revised accepted: 29 July 2022

Abstract

**Purpose:** To evaluate the role of homebox C10 (HOXC10) in nasopharyngeal carcinoma (NPC).

**Methods:** Cell Counting Kit-8 (CCK-8) and colony formation assays were conducted to determine NPC cell proliferation. Cell migration and invasion were assessed using a Transwell assay, while western blot was used to investigate the mechanism of action involved in HOXC10-mediated NPC.

**Results:** HOXC10 levels were significantly elevated in NPC cells (p < 0.001). Over-expression of HOXC10 significantly increased NPC cell viability (p < 0.05) and proliferation. However, silencing HOXC10 reduced NPC cell proliferation. HOXC10 knockdown suppressed NPC cell migration and invasion. NPC expression of phosphorylated phosphoinositide-3-kinase (PI3K) and protein kinase B (AKT) proteins were up-regulated after HOXC10 over-expression but were down-regulated upon silencing HOXC10 (p < 0.05).

**Conclusion:** HOXC10 knockdown reduces NPC cell proliferation and metastasis by inactivating PI3K/AKT pathway, and therefore, can potentially be developed for the treatment of nasopharyngeal carcinoma.

**Keywords:** HOXC10, Nasopharyngeal carcinoma, Cell proliferation, Cell migration, Invasion, PI3K/AKT

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

INTRODUCTION

Nasopharyngeal carcinoma (NPC) is an epithelial malignant tumor that originates from the nasopharyngeal mucosa [1]. NPC has a high incidence and prevalence in Southeast Asia and China, which account for nearly 40% of new NPC cases worldwide [2]. Although the combination of radiotherapy and chemotherapy has significantly improved NPC treatment, patient prognosis is poor due to the high metastasis of NPC [3]. Homebox (HOX) genes impact embryogenesis by encoding transcriptional factors that regulate the determination of cell identity [4]. Moreover, the dysregulation of HOX genes is closely associated with human malignancies. HOX genes function either as tumor suppressors or oncogenes in diverse tumors [4]. There are four distinct clusters of HOX genes, which are HOXA, HOXB, HOXC, and HOXD. Homeobox C10

Tropical Journal of Pharmaceutical Research August 2022; 21 (8): 1595-1600
ISSN: 1596-5996 (print); 1596-9827 (electronic)
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 200001 Nigeria

Available online at http://www.tjpr.org
http://dx.doi.org/10.4314/tjpr.v21i8.3

© 2022 The authors. This work is licensed under the Creative Commons Attribution 4.0 International License
(HOXC10) belongs to the HOXC cluster and functions as an oncogene in various tumors [5]. For example, HOXC10 is up-regulated in colorectal cancer [6], and high HOXC10 expression is correlated with a poor prognosis for basal-like breast cancer [7]. HOXC10 overexpression led to the metastasis and tumorigenesis of hepatocellular carcinoma [8] and silencing HOXC10 repressed gastric cancer tumor cell proliferation and metastasis [9]. Moreover, HOXC10 also conferred resistance to chemoradiotherapy in breast cancer [10] and esophageal squamous cell carcinoma cells [11]. However, the role and mechanism of action of HOXC10 in NPC remain unclear.

The phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt) pathway is constitutively activated in NPC [12], and blocking the PI3K/Akt pathway suppresses NPC metastasis [13]. HOXC10 binds to the promoter region of erb-b2 receptor tyrosine kinase 3, which promotes PI3K phosphorylation, activating the PI3K/Akt pathway [11]. Therefore, regulating the PI3K/Akt pathway may allow HOXC10 to regulate NPC tumorigenesis.

This study aimed to investigate the effect of HOXC10 on NPC cell proliferation, invasion, and migration, as well as assess the mechanism of action involved, which may ultimately reveal a potential target for NPC treatment.

**EXPERIMENTAL**

**Cell culture and transfection**

The NPC cell lines C666-1, SUNE-1, 5-8F, and 6-10B, and human nasopharyngeal epithelial cell line NP69 were grown in Roswell Park Memorial Institute (RPMI) medium 1640 (GibCo BRL, Grand Island, NY, USA) containing 10 % fetal bovine serum (Thermo Fisher Scientific, Waltham, MA, USA) in a 37 °C incubator. Full-length HOXC10 was subcloned into the pcDNA-3.1 vector (Invitrogen, Carlsbad, CA, USA) to generate pcDNA-HOXC10. The siRNA targeting HOXC10 (si-HOXC10) was synthesized by GenePharma (Suzhou, China). C666-1 and 5-8F cells were transfected with siRNAs (si-HOXC10 and si-NC) or pcDNAs (pcDNA-HOXC10 and pcDNA) using Lipofectamine 2000 (Invitrogen) for 24 hours.

**Quantitative reverse transcription polymerase chain reaction (qRT-PCR)**

Cells were lysed in TRIzol (Invitrogen) in order to isolate total RNA. The isolated total RNA was then reverse transcribed into cDNA using the Multiscribe™ reverse transcription kit (Applied Biosystems, CA, USA). The mRNA expression of HOXC10 was assessed using the PreTaq II kit (Takara, Dalian, Liaoing, China) and normalized using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the internal control. Primer sequences are shown in Table 1.

**Table 1: Primer sequences for qRT-PCR**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOXC10</td>
<td>5'-ATCGAATTCTAGTAATCCCTGAGTGGAATTCATG-3'</td>
<td>5'-ATCGAATTCTAGTATCCCTGAGTGGAATTCATG-3'</td>
</tr>
<tr>
<td>GAPDH</td>
<td>5'-GGCATGGACTGCAATGT-3'</td>
<td>5'-GGCATGGACTGCAATGT-3'</td>
</tr>
</tbody>
</table>

**Cell viability and proliferation assays**

To measure cell viability, C666-1 and 5-8F (1 x 10^6) were seeded into a 96-well plate and transfected as indicated for 24 hours. Cells were then grown for an additional 24, 48, 72, or 96 hours. Cell counting kit 8 (CCK8) solution (Beyotime, Beijing, China) was then added to each well and incubated for 2 hours. Absorbance at 490 nm was measured using a microplate reader (Thermo Fisher Scientific). To determine cell proliferation, C666-1 and 5-8F cells were seeded in a 6-well plate and were subsequently transfected as indicated. Cells were grown in the 37 °C incubator for ten days. Cell colonies were fixed in methanol and stained with 0.1 % crystal violet (Sigma-Aldrich, St. Louis, MO, USA). The colonies were photographed under a light microscope (Olympus, Tokyo, Japan).

**Transwell assay**

To assess cell migration, C666-1 and 5-8F cells in serum-free medium were plated in upper transwell insert chambers (Corning Incorporated, Corning, NY, USA). Culture medium containing 15 % fetal bovine serum was plated in the lower chamber. Invasive cells in the lower chamber were stained with crystal violet and observed with a microscope (Olympus) 24 hours after plating. To determine cell invasion, C666-1 and 5-8F cells in serum-free medium were also plated in the Matrigel-coated upper chambers, and invasive cells were stained and observed using a microscope (Olympus) 24 hours post-plating.

**Western blot assay**

C666-1 and 5-8F cells were lysed in RIPA buffer (Beyotime). Lysates were centrifuged at 12000 × g for 60 minutes, and the supernatant was
collected. Supernatant protein concentration was determined using a BCA Protein Assay Kit (Beyotime). Protein samples of the supernatant were separated on a 10 % sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. Proteins were transferred onto nitrocellulose membranes and blocked with 5 % bovine serum albumin. The membranes were then probed at 4 °C with the following antibodies: anti-GAPDH (1:2000), anti-p-PI3K and anti-PI3K (1:3000), anti-p-AKT and anti-AKT (1:4000). The membranes were then washed using PBS-T and incubated with a horseradish peroxidase-conjugated secondary antibody (1:5000). Immunoreactivities were visualized using enhanced chemiluminescence (Sigma-Aldrich) and normalized to GAPDH as the internal control. All antibodies were acquired from Abcam (Cambridge, MA, USA).

Statistical analysis

All data with at least three replicates are expressed as mean ± standard error of the mean (SEM). Data were analyzed using either a Student’s t-test or a one-way analysis of variance (ANOVA) using Statistical Package for the Social Sciences (SPSS) software 11.5 (IBM, Chicago, IL, USA). *P < 0.05 was considered statistically significant.

RESULTS

HOXC10 is elevated in NPC

Compared to the human nasopharyngeal epithelial cell line NP69, HOXC10 mRNA expression was significantly up-regulated in NPC cell lines C666-1, SUNE-1, 5-8F, and 6-10B (Figure 1 A). Furthermore, HOXC10 protein expression was also increased in NPC cells compared to NP69 (Figure 1 B), suggesting a possible relationship between HOXC10 and NPC.

HOXC10 contributes to NPC cell proliferation

C666-1 and 5-8F cell viability increased after transfection with pcDNA-HOXC10, a construct that overexpresses HOXC10 (Figure 2 A). However, knockdown of HOXC10 after transfection with si-HOXC10 decreased C666-1 and 5-8F cell viability (Figure 2A). Moreover, the number of C666-1 and 5-8F colonies was enhanced by HOXC10 over-expression but was reduced by HOXC10 knockdown (Figure 2 B). These findings show that HOXC10 promotes NPC cell proliferation.

Figure 1: HOXC10 expression is elevated in NPC cells. (A) The mRNA expression of HOXC10 was significantly up-regulated in NPC cell lines C666-1, SUNE-1, 5-8F, and 6-10B compared to the human nasopharyngeal epithelial cell line NP69. (B) HOXC10 protein expression was significantly up-regulated in NPC cells compared to NP69 cells. **P < 0.01, ***P < 0.001

Figure 2: HOXC10 contributes to NPC cell proliferation. (A) C666-1 and 5-8F cell viability increased after pcDNA-HOXC10 transfection and decreased after si-HOXC10 transfection. (B) C666-1 and 5-8F cell proliferation increased after pcDNA-HOXC10 transfection and decreased after si-HOXC10 transfection. *, # P < 0.05. *** *, ### , ### , P < 0.001

HOXC10 promotes NPC cell metastasis

Invasion of C666-1 and 5-8F cells was suppressed by HOXC10 silencing and promoted by HOXC10 over-expression (Figure 3 A). Additionally, the number of migratory C666-1 and 5-8F cells increased after HOXC10 over-expression and decreased after HOXC10 knockdown (Figure 3 B), indicating the metastatic effect of HOXC10 expression in NPC.

HOXC10 stimulates PI3K/AKT activation in NPC

Either over-expressing or silencing HOXC10 did not affect PI3K and AKT protein expression in C666-1 and 5-8F cells (Figure 4). However, expression of p-PI3K and p-AKT decreased after HOXC10 silencing and increased upon HOXC10
over-expression (Figure 4), revealing that HOXC10 activates PI3K and AKT in NPC cells.

We found that HOXC10 expression was elevated in NPC cells. High HOXC10 expression is positively correlated with poor patient prognosis and poor tumor pathological staging [5]. Therefore, HOXC10 may also function as a diagnostic or prognostic biomarker of NPC. However, the relationship between HOXC10 and the clinical indicators of NPC patients requires further investigation.

HOXC10 over-expression enhances tumor proliferation, recrudescence, invasiveness, and drug resistance [5]. Our present study also shows that NPC cell proliferation, invasion, and migration were promoted during high HOXC10 expression but were suppressed by low HOXC10 expression. Dysregulation of HOXC10 contributes to tumorigenesis through regulating cell angiogenesis and epithelial-to-mesenchymal transition [5]. Further investigation is required to understand the effects of HOXC10 on the NPC cell cycle, apoptosis, and epithelial-to-mesenchymal transition.

Aberrant activation of PI3K/AKT signaling contributes to NPC tumorigenesis and carcinogenic transformation through the regulation of autophagy, cell metastasis, apoptosis, and proliferation [16]. HOXC10 elevation enhances PI3K phosphorylation, up-regulates the genes involved in the PI3K/AKT pathway, and accelerates cancer progression [11]. Furthermore, HOXC10 knockdown reduces PI3K phosphorylation and inhibits the metastasis of lung adenocarcinoma [17].

The results of this study have demonstrated that PI3K and AKT phosphorylation were down-regulated by silencing HOXC10 and up-regulated during HOXC10 over-expression. Thus, HOXC10 promotes the aberrant activation of PI3K/AKT signaling, which intensifies tumor progression.

CONCLUSION

HOXC10 is elevated in NPC, but over-expression of HOXC10 enhances NPC cell proliferation, invasion, and migration. Moreover, HOXC10 knockdown represses NPC cell proliferation and metastasis by inactivating PI3K/AKT signaling. However, the in vivo effects of HOXC10 on NPC tumor growth remain to be examined.

DECLARATIONS

Acknowledgements

None provided.
Funding
None provided.

Ethical approval
None provided.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflict of Interest
No conflict of interest associated with this work.

Contribution of Authors
We declare that this work was performed by the authors named in this article, and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. Liping Wu and Guohong Qian designed and performed the experiments. Yuqing Zheng analyzed and interpreted the data. Huizhen Zheng prepared the manuscript with contributions from all co-authors.

Open Access
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

Trop J Pharm Res, August 2022; 21(8): 1599